Government, business and industry leaders came together to celebrate the opening and dedication of the headquarters and 24,000-square-feet of laboratory space for H3 Biomedicine Inc., a new privately held, uniquely structured drug discovery company that is integrating human cancer genetics with next-generation synthetic chemistry to generate novel small-molecule drugs to treat cancer.

With a $200-million research funding commitment from the global human health care company, Eisai, and access to its worldwide development capabilities, H3 Biomedicine is well positioned to address some of the most challenging cancers by delivering on its scientific vision of patient-based, genomics-driven drug discovery.

H3 Biomedicine is growing rapidly and creating a dynamic, entrepreneurial environment where its team members will focus on scientific excellence. H3 Biomedicine leadership expects to expand its team in Cambridge, Massachusetts to 70 employees by end of 2012.